September 27, 2016 4:16 AM ET

Healthcare Equipment and Supplies

Company Overview of Sera Prognostics, Inc.

Company Overview

Sera Prognostics, Inc. is a biotechnology company that develops diagnostic tests for the early prediction of a woman’s individualized risk of premature birth, preeclampsia, and other pregnancy complications. It focuses on addressing the economic and healthcare burden that premature birth places on infants, their families, and society. The company was founded in 2008 and is based in Salt Lake City, Utah.

2749 East Parleys Way

Suite 200

Salt Lake City, UT 84109

United States

Founded in 2008

Phone:

801-505-0278

Fax:

801-505-0280

Key Executives for Sera Prognostics, Inc.

Executive Chairman, Chief Executive Officer and President
Age: 63
Co-Founder, Managing Director of the Seed Fund Upstart Ventures and Director
Co-Founder and Co-Chairman of The Scientific Advisory Board
Co-Founder and Co-Chairman of Scientific Advisory Board
Chief Financial Officer
Age: 49
Compensation as of Fiscal Year 2016.

Sera Prognostics, Inc. Key Developments

Sera Prognostics, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-14-2016 09:30 AM

Sera Prognostics, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-14-2016 09:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Gregory C. Critchfield, Executive Chairman, Chief Executive Officer and President.

Sera Prognostics, Inc. Presents at 27th Annual Piper Jaffray Healthcare Conference, Dec-02-2015 10:30 AM

Sera Prognostics, Inc. Presents at 27th Annual Piper Jaffray Healthcare Conference, Dec-02-2015 10:30 AM. Venue: Lotte New York Palace, New York, New York, United States. Speakers: Gregory C. Critchfield, Executive Chairman, Chief Executive Officer and President.

Sera Prognostics, Inc. Announces Early Limited Commercial Access of PreTRM™ Test

Sera Prognostics, Inc. announced a program for early limited commercial access to PreTRM™, a proteomic biomarker blood test designed to provide an early, objective, and individualized assessment of a woman’s risk of preterm birth. The test will be made available in limited locations in the U.S., beginning with selected clinical sites that participated in the Proteomic Assessment of Preterm Risk (PAPR) study. All PreTRM™ testing will be conducted at Sera's CLIA-certified laboratory in response to orders from women’s health care professionals. Following the early access outreach to physicians in selected markets this fall, Sera is planning for a wider national PreTRM™ rollout in 2016.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sera Prognostics, Inc., please visit www.seraprognostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.